menu
    • menu

    Company profile for InflaRx

    NEW Drugs in Dev: 7
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena an...
    InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary anti-C5a technology to discover and develop first-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InflaRxGermany Flag
    Country
    Country
    Germany
    Address
    Address
    InflaRx N.V. Winzerlaer Str. 2 07745 Jena
    Telephone
    Telephone
    +49 (0)3641 508 180
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.inflarx.de/Home.html
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    InflaRx Closes $150M Underwritten Offering of Ordinary Shares
    InflaRx Closes $150M Underwritten Offering of Ordinary Shares

    08 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/08/3291046/0/en/inflarx-announces-closing-of-150-million-underwritten-offering-of-ordinary-shares.html

    GLOBENEWSWIRE
    08 May 2026
    Share Share
    InflaRx Advances Izicopan in ANCA-Associated Vasculitis
    InflaRx Advances Izicopan in ANCA-Associated Vasculitis

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288799/0/en/inflarx-announces-advancement-of-izicopan-in-anca-associated-vasculitis-and-select-renal-diseases.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    InflaRx Prices $150M Underwritten Ordinary Share Offering
    InflaRx Prices $150M Underwritten Ordinary Share Offering

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288823/0/en/inflarx-announces-pricing-of-150-million-underwritten-offering-of-ordinary-shares.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    InflaRx: Favorable Izicopan Metabolite Profile in Humans
    InflaRx: Favorable Izicopan Metabolite Profile in Humans

    04 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/04/3286600/0/en/inflarx-reports-favorable-reactive-metabolite-profile-for-izicopan-in-human-liver-microsomes.html

    GLOBENEWSWIRE
    04 May 2026
    Share Share
    Inflarx To Report First Quarter 2026 Results On May 7, 2026
    Inflarx To Report First Quarter 2026 Results On May 7, 2026

    01 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/01/3285846/0/en/inflarx-to-report-first-quarter-2026-results-on-may-7-2026.html

    GLOBENEWSWIRE
    01 May 2026
    Share Share
    InflaRx Regains Compliance with Nasdaq Bid Price Requirement
    InflaRx Regains Compliance with Nasdaq Bid Price Requirement

    28 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/28/3282490/0/en/inflarx-regains-compliance-with-nasdaq-minimum-bid-price-requirement.html

    GLOBENEWSWIRE
    28 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search